Community-acquired pneumonia (CAP) remains a major cause of hospitalization and mortality worldwide. Respiratory fluoroquinolones such as moxifloxacin and levofloxacin are recommended as empirical therapy for hospitalized CAP patients without resistant pathogen risk factors.This review article aimed to compare the efficacy and safety of moxifloxacin and levofloxacin as monotherapy in hospitalized CAP patients. Literature search was conducted through PubMed, Scopus, and ScienceDirect databases for publications between 2016–2026. Clinical cure rate, minimum inhibitory concentration (MIC), epithelial lining fluid (ELF) penetration, pharmacokinetic/pharmacodynamic parameters, and adverse event profiles were analyzed. The findings indicate that moxifloxacin demonstrates higher clinical cure rates, lower MIC values against major respiratory pathogens, and greater ELF penetration compared to levofloxacin. Both agents show comparable safety profiles; however, moxifloxacin is more associated with QT interval prolongation, whereas levofloxacin presents higher risk of severe hypoglycemia in diabetic patients. Overall, moxifloxacin appears superior as empirical therapy for hospitalized CAP with appropriate patient selection.
Copyrights © 2026